Cargando…

A lipid metabolism–based prognostic risk model for HBV–related hepatocellular carcinoma

BACKGROUND: Up to 85% of hepatocellular carcinoma (HCC) cases in China can be attributed to infection of hepatitis B virus (HBV). Lipid metabolism performs important function in hepatocarcinogenesis of HBV–related liver carcinoma. However, limited studies have explored the prognostic role of lipid m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Lili, Xia, Shaohuai, Liu, Yaoyao, Ji, Qiang, Li, Lifeng, Gao, Xuan, Guo, Xiaodi, Yi, Xin, Chen, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067291/
https://www.ncbi.nlm.nih.gov/pubmed/37004044
http://dx.doi.org/10.1186/s12944-023-01780-9
_version_ 1785018433191018496
author Zhou, Lili
Xia, Shaohuai
Liu, Yaoyao
Ji, Qiang
Li, Lifeng
Gao, Xuan
Guo, Xiaodi
Yi, Xin
Chen, Feng
author_facet Zhou, Lili
Xia, Shaohuai
Liu, Yaoyao
Ji, Qiang
Li, Lifeng
Gao, Xuan
Guo, Xiaodi
Yi, Xin
Chen, Feng
author_sort Zhou, Lili
collection PubMed
description BACKGROUND: Up to 85% of hepatocellular carcinoma (HCC) cases in China can be attributed to infection of hepatitis B virus (HBV). Lipid metabolism performs important function in hepatocarcinogenesis of HBV–related liver carcinoma. However, limited studies have explored the prognostic role of lipid metabolism in HBV–related HCC. This study established a prognostic model to stratify HBV–related HCC based on lipid metabolisms. METHODS: Based on The Cancer Genome Atlas HBV–related HCC samples, this study selected prognosis-related lipid metabolism genes and established a prognosis risk model by performing uni- and multi-variate Cox regression methods. The final markers used to establish the model were selected through the least absolute shrinkage and selection operator method. Analysis of functional enrichment, immune landscape, and genomic alteration was utilized to investigate the inner molecular mechanism involved in prognosis. RESULTS: The risk model independently stratified HBV-infected patients with liver cancer into two risk groups. The low–risk groups harbored longer survival times (with P < 0.05, log–rank test). TP53, LRP1B, TTN, and DNAH8 mutations and high genomic instability occurred in high–risk groups. Low–risk groups harbored higher CD8 T cell infiltration and BTLA expression. Lipid–metabolism (including “Fatty acid metabolism”) and immune pathways were significantly enriched (P < 0.05) in the low–risk groups. CONCLUSIONS: This study established a robust model to stratify HBV–related HCC effectively. Analysis results decode in part the heterogeneity of HBV–related liver cancer and highlight perturbation of lipid metabolism in HBV–related HCC. This study’s findings could facilitate patients’ clinical classification and give hints for treatment selection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12944-023-01780-9.
format Online
Article
Text
id pubmed-10067291
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100672912023-04-03 A lipid metabolism–based prognostic risk model for HBV–related hepatocellular carcinoma Zhou, Lili Xia, Shaohuai Liu, Yaoyao Ji, Qiang Li, Lifeng Gao, Xuan Guo, Xiaodi Yi, Xin Chen, Feng Lipids Health Dis Research BACKGROUND: Up to 85% of hepatocellular carcinoma (HCC) cases in China can be attributed to infection of hepatitis B virus (HBV). Lipid metabolism performs important function in hepatocarcinogenesis of HBV–related liver carcinoma. However, limited studies have explored the prognostic role of lipid metabolism in HBV–related HCC. This study established a prognostic model to stratify HBV–related HCC based on lipid metabolisms. METHODS: Based on The Cancer Genome Atlas HBV–related HCC samples, this study selected prognosis-related lipid metabolism genes and established a prognosis risk model by performing uni- and multi-variate Cox regression methods. The final markers used to establish the model were selected through the least absolute shrinkage and selection operator method. Analysis of functional enrichment, immune landscape, and genomic alteration was utilized to investigate the inner molecular mechanism involved in prognosis. RESULTS: The risk model independently stratified HBV-infected patients with liver cancer into two risk groups. The low–risk groups harbored longer survival times (with P < 0.05, log–rank test). TP53, LRP1B, TTN, and DNAH8 mutations and high genomic instability occurred in high–risk groups. Low–risk groups harbored higher CD8 T cell infiltration and BTLA expression. Lipid–metabolism (including “Fatty acid metabolism”) and immune pathways were significantly enriched (P < 0.05) in the low–risk groups. CONCLUSIONS: This study established a robust model to stratify HBV–related HCC effectively. Analysis results decode in part the heterogeneity of HBV–related liver cancer and highlight perturbation of lipid metabolism in HBV–related HCC. This study’s findings could facilitate patients’ clinical classification and give hints for treatment selection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12944-023-01780-9. BioMed Central 2023-04-01 /pmc/articles/PMC10067291/ /pubmed/37004044 http://dx.doi.org/10.1186/s12944-023-01780-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhou, Lili
Xia, Shaohuai
Liu, Yaoyao
Ji, Qiang
Li, Lifeng
Gao, Xuan
Guo, Xiaodi
Yi, Xin
Chen, Feng
A lipid metabolism–based prognostic risk model for HBV–related hepatocellular carcinoma
title A lipid metabolism–based prognostic risk model for HBV–related hepatocellular carcinoma
title_full A lipid metabolism–based prognostic risk model for HBV–related hepatocellular carcinoma
title_fullStr A lipid metabolism–based prognostic risk model for HBV–related hepatocellular carcinoma
title_full_unstemmed A lipid metabolism–based prognostic risk model for HBV–related hepatocellular carcinoma
title_short A lipid metabolism–based prognostic risk model for HBV–related hepatocellular carcinoma
title_sort lipid metabolism–based prognostic risk model for hbv–related hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067291/
https://www.ncbi.nlm.nih.gov/pubmed/37004044
http://dx.doi.org/10.1186/s12944-023-01780-9
work_keys_str_mv AT zhoulili alipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT xiashaohuai alipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT liuyaoyao alipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT jiqiang alipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT lilifeng alipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT gaoxuan alipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT guoxiaodi alipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT yixin alipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT chenfeng alipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT zhoulili lipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT xiashaohuai lipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT liuyaoyao lipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT jiqiang lipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT lilifeng lipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT gaoxuan lipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT guoxiaodi lipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT yixin lipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma
AT chenfeng lipidmetabolismbasedprognosticriskmodelforhbvrelatedhepatocellularcarcinoma